Skip to main content
OpenTrials
Completed

NCT Number: NCT04097106

Synbiotic Dietary Supplement and Gut Microbiota

To test the feasibility and safety of our designer synbiotic on gastrointestinal symptoms and gut microbiota and fecal metabolomics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Kassandra Spates-Harden

Cleveland, Ohio, 44101, United States

About this study

This will be a double-blinded, randomized, placebo-controlled paired crossover pilot study in healthy controls aimed to evaluate gastrointestinal tolerance of a synbiotic dietary supplement.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI 19-25 (lean) and BMI 30-35 (obese)
  • Age 18-45 years old
  • subjects must be willing to consume oral dietary supplement and placebo daily for a total of 56 days,
  • willing to complete gastrointestinal (GI) and dietary surveys, body composition assessment, and provide blood, urine and stool sample at 4 intervals during the pilot study (baseline, after first supplementation period (day 28), after washout period (day 49), and after second supplementation period (day 77)

Exclusion criteria

  • antibiotic consumption within 28 days of study initiation
  • diabetes
  • kidney disorders
  • history of cardiac disease and medications for cardiac disease
  • use of statins and antihypertensive drugs
  • inflammatory bowel disease
  • irritable bowel syndrome
  • history of small intestinal bacterial overgrowth
  • history of intestinal surgery, excluding hernia repair and appendectomy
  • active cancer diagnosis; chronic acid suppression treatment (proton pump inhibitors, histamine H2 receptor antagonists)
  • immune modulatory treatments (e.g. chronic immunosuppressive medications, chronic NSAIDs)
  • abnormal liver or kidney function as measured by routine serum chemistry testing
  • severe anemia or significant white blood cell or platelet abnormalities
  • no additional blood or blood product donations during study

Treatment and study plan

Synbiotic

Dietary Supplement

Synbiotic dietary supplement in capsule form

Primary outcomes

  1. Measure change in gastrointestinal symptoms using "Rating of Gastrointestinal (GI) Symptoms" scale

    Time frame: Baseline, Day 28, day 49, day 77

    Rating of GI Symptoms scale includes 5 questions, which range from 0 (never affected) to 7 (always bothered), summed to compute total score

  2. Change in microbiome stool diversity

    Time frame: Baseline, Day 28, day 49, day 77

  3. Change in metabolome stool profile

    Time frame: Baseline, Day 28, day 49, day 77

  4. Change in metabolome urine profile

    Time frame: Baseline, Day 28, day 49, day 77

Sponsors and collaborators

Lead sponsor

The Cleveland Clinic

Other

Registry information

Official study title

Synbiotic Supplement Effects on Gastrointestinal Symptoms and Gut Microbiota and Fecal Metabolomics

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Sep 20, 2019
Registry last updated
Dec 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.